Analystreport

Xenon Pharmaceuticals (NASDAQ:XENE) had its price target raised by analysts at JPMorgan Chase & Co. from $57.00 to $60.00. They now have an "overweight" rating on the stock.

Xenon Pharmaceuticals Inc. - Common Shares  (XENE) 
Last xenon pharmaceuticals inc. - common shares earnings: 11/5 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.xenon-pharma.com